High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma

A. Kessinger, James Olen Armitage, D. M. Smith, J. D. Landmark, Philip Jay Bierman, D. D. Weisenburger

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation. Disappearance of circulating neutrophils and development of RBC and platelet transfusion-dependence was followed, in the evaluable patients, by reappearance of 0.5 x 109/L circulating granulocytes and sufficient platelets to obviate the need for platelet transfusions at a median of 25 days after transplantation. Twenty-three patients experienced a clinical complete remission (CR). The projected 2-year event-free survival was 25% for all 40 patients and 49% for the non-Hodgkin's lymphoma patients. The projected 18-month event-free survival for the Hodgkin's disease patients was 15%. PB stem cell transplantation provided an opportunity to administer high-dose salvage therapy to patients with refractory lymphoma who otherwise were not candidates for such therapy. For some of those patients, the high-dose therapy produced prolonged survival, free of tumor progression.

Original languageEnglish (US)
Pages (from-to)1260-1265
Number of pages6
JournalBlood
Volume74
Issue number4
StatePublished - Jan 1 1989

Fingerprint

Peripheral Blood Stem Cell Transplantation
Platelets
Stem cells
Lymphoma
Blood
Refractory materials
Tumors
Salvaging
Bone
Disease-Free Survival
Therapeutics
Platelet Transfusion
Irradiation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Bone Marrow
Salvage Therapy
Autologous Transplantation
Hematopoietic Stem Cell Transplantation
Bone Marrow Transplantation

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Kessinger, A., Armitage, J. O., Smith, D. M., Landmark, J. D., Bierman, P. J., & Weisenburger, D. D. (1989). High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood, 74(4), 1260-1265.

High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. / Kessinger, A.; Armitage, James Olen; Smith, D. M.; Landmark, J. D.; Bierman, Philip Jay; Weisenburger, D. D.

In: Blood, Vol. 74, No. 4, 01.01.1989, p. 1260-1265.

Research output: Contribution to journalArticle

Kessinger, A, Armitage, JO, Smith, DM, Landmark, JD, Bierman, PJ & Weisenburger, DD 1989, 'High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma', Blood, vol. 74, no. 4, pp. 1260-1265.
Kessinger, A. ; Armitage, James Olen ; Smith, D. M. ; Landmark, J. D. ; Bierman, Philip Jay ; Weisenburger, D. D. / High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. In: Blood. 1989 ; Vol. 74, No. 4. pp. 1260-1265.
@article{c3ba5b8958ec49ff9ba02021e894d75a,
title = "High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma",
abstract = "Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation. Disappearance of circulating neutrophils and development of RBC and platelet transfusion-dependence was followed, in the evaluable patients, by reappearance of 0.5 x 109/L circulating granulocytes and sufficient platelets to obviate the need for platelet transfusions at a median of 25 days after transplantation. Twenty-three patients experienced a clinical complete remission (CR). The projected 2-year event-free survival was 25{\%} for all 40 patients and 49{\%} for the non-Hodgkin's lymphoma patients. The projected 18-month event-free survival for the Hodgkin's disease patients was 15{\%}. PB stem cell transplantation provided an opportunity to administer high-dose salvage therapy to patients with refractory lymphoma who otherwise were not candidates for such therapy. For some of those patients, the high-dose therapy produced prolonged survival, free of tumor progression.",
author = "A. Kessinger and Armitage, {James Olen} and Smith, {D. M.} and Landmark, {J. D.} and Bierman, {Philip Jay} and Weisenburger, {D. D.}",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
volume = "74",
pages = "1260--1265",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma

AU - Kessinger, A.

AU - Armitage, James Olen

AU - Smith, D. M.

AU - Landmark, J. D.

AU - Bierman, Philip Jay

AU - Weisenburger, D. D.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation. Disappearance of circulating neutrophils and development of RBC and platelet transfusion-dependence was followed, in the evaluable patients, by reappearance of 0.5 x 109/L circulating granulocytes and sufficient platelets to obviate the need for platelet transfusions at a median of 25 days after transplantation. Twenty-three patients experienced a clinical complete remission (CR). The projected 2-year event-free survival was 25% for all 40 patients and 49% for the non-Hodgkin's lymphoma patients. The projected 18-month event-free survival for the Hodgkin's disease patients was 15%. PB stem cell transplantation provided an opportunity to administer high-dose salvage therapy to patients with refractory lymphoma who otherwise were not candidates for such therapy. For some of those patients, the high-dose therapy produced prolonged survival, free of tumor progression.

AB - Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation. Disappearance of circulating neutrophils and development of RBC and platelet transfusion-dependence was followed, in the evaluable patients, by reappearance of 0.5 x 109/L circulating granulocytes and sufficient platelets to obviate the need for platelet transfusions at a median of 25 days after transplantation. Twenty-three patients experienced a clinical complete remission (CR). The projected 2-year event-free survival was 25% for all 40 patients and 49% for the non-Hodgkin's lymphoma patients. The projected 18-month event-free survival for the Hodgkin's disease patients was 15%. PB stem cell transplantation provided an opportunity to administer high-dose salvage therapy to patients with refractory lymphoma who otherwise were not candidates for such therapy. For some of those patients, the high-dose therapy produced prolonged survival, free of tumor progression.

UR - http://www.scopus.com/inward/record.url?scp=0024465762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024465762&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 1260

EP - 1265

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -